Medico Remedies Limited - Asset Resilience Ratio
Medico Remedies Limited (MEDICO) has an Asset Resilience Ratio of 1.20% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check MEDICO strategic asset allocation to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2026)
This chart shows how Medico Remedies Limited's Asset Resilience Ratio has changed over time. See Medico Remedies Limited balance sheet independence to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Medico Remedies Limited's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Medico Remedies Limited market cap and net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Rs0.00 | 0% |
| Short-term Investments | Rs18.44 Million | 1.2% |
| Total Liquid Assets | Rs18.44 Million | 1.20% |
Asset Resilience Insights
- Limited Liquidity: Medico Remedies Limited maintains only 1.20% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Medico Remedies Limited Industry Peers by Asset Resilience Ratio
Compare Medico Remedies Limited's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603 |
Drug Manufacturers - Specialty & Generic | 11.60% |
|
SIMCERE PHARMAC. GRP LTD
F:S2P |
Drug Manufacturers - Specialty & Generic | 0.44% |
|
Curaleaf Holdings Inc.
TO:CURA |
Drug Manufacturers - Specialty & Generic | 3.73% |
|
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755 |
Drug Manufacturers - Specialty & Generic | 24.59% |
|
Walvax BioTech
SHE:300142 |
Drug Manufacturers - Specialty & Generic | 2.20% |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091 |
Drug Manufacturers - Specialty & Generic | 26.36% |
|
Cronos Group Inc
TO:CRON |
Drug Manufacturers - Specialty & Generic | 69.94% |
|
Renhe Pharmacy Co Ltd
SHE:000650 |
Drug Manufacturers - Specialty & Generic | 37.54% |
Annual Asset Resilience Ratio for Medico Remedies Limited (2016–2026)
The table below shows the annual Asset Resilience Ratio data for Medico Remedies Limited.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2026-03-31 | 1.20% | Rs18.44 Million ≈ $199.45K |
Rs1.53 Billion ≈ $16.59 Million |
-0.01pp |
| 2025-03-31 | 1.21% | Rs14.51 Million ≈ $156.88K |
Rs1.20 Billion ≈ $12.96 Million |
-0.21pp |
| 2024-03-31 | 1.42% | Rs13.63 Million ≈ $147.41K |
Rs961.95 Million ≈ $10.40 Million |
-0.03pp |
| 2023-03-31 | 1.45% | Rs12.66 Million ≈ $136.88K |
Rs874.48 Million ≈ $9.46 Million |
-0.10pp |
| 2022-03-31 | 1.55% | Rs11.79 Million ≈ $127.49K |
Rs761.90 Million ≈ $8.24 Million |
+0.15pp |
| 2021-03-31 | 1.40% | Rs10.56 Million ≈ $114.18K |
Rs756.21 Million ≈ $8.18 Million |
+0.39pp |
| 2020-03-31 | 1.01% | Rs7.60 Million ≈ $82.19K |
Rs752.69 Million ≈ $8.14 Million |
+0.42pp |
| 2019-03-31 | 0.59% | Rs4.50 Million ≈ $48.67K |
Rs763.09 Million ≈ $8.25 Million |
-0.46pp |
| 2018-03-31 | 1.05% | Rs6.22 Million ≈ $67.29K |
Rs593.85 Million ≈ $6.42 Million |
+1.02pp |
| 2017-03-31 | 0.02% | Rs120.39K ≈ $1.30K |
Rs482.46 Million ≈ $5.22 Million |
+0.36pp |
| 2016-03-31 | -0.33% | Rs-1.52 Million ≈ $-16.39K |
Rs455.43 Million ≈ $4.93 Million |
-- |
About Medico Remedies Limited
Medico Remedies Limited develops, manufactures, and sells pharmaceutical and nutraceutical products in India. The company offers antibiotics and anti-infectives; beta-lactams-penicillins and cephalosporins; antifungals; vitamins and supplements; cardiovascular products; antipyretic, analgesic, and NSAIDs medicines; antacid and anti-ulcer drugs; antidepressants, antipsychotics, and anti-epileptics… Read more